![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/16/2883392/0/en/Nuvectis-Pharma-Inc-to-Present-at-the-H-C-Wainwright-BioConnect-Investor-Conference.html
https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html
https://www.globenewswire.com/news-release/2024/04/08/2859189/0/en/Nuvectis-Pharma-s-NXP900-Demonstrates-Robust-Activity-in-Non-Small-Cell-Lung-Cancer-Cell-Lines.html
https://www.globenewswire.com/news-release/2024/03/19/2848489/0/en/Nuvectis-Pharma-Announces-Upcoming-Presentations-at-the-2024-American-Association-for-Cancer-Research-Meeting.html
https://www.globenewswire.com//news-release/2024/03/15/2847001/0/en/Nuvectis-Pharma-to-Present-at-the-36th-Annual-Roth-Conference.html
https://www.globenewswire.com//news-release/2024/03/14/2846324/0/en/Nuvectis-Pharma-Announces-Encouraging-Preliminary-Data-from-the-NXP800-Phase-1b-Clinical-Trial-in-Platinum-Resistant-ARID1a-Mutated-Ovarian-Cancer.html
https://www.globenewswire.com//news-release/2024/03/05/2840404/0/en/Nuvectis-Pharma-Inc-Reports-Fiscal-Year-2023-Financial-Results-and-Business-Highlights.html
https://www.globenewswire.com//news-release/2024/02/09/2826812/0/en/Correction-Nuvectis-Pharma-Announces-Participation-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/01/03/2803238/0/en/Nuvectis-Pharma-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/12/18/2797787/0/en/Nuvectis-Pharma-Inc-Announces-a-Collaboration-with-Mayo-Clinic-to-Evaluate-NXP800-in-an-Investigator-Sponsored-Clinical-Trial-in-Cholangiocarcinoma.html